Copyright
©The Author(s) 2016.
World J Gastroenterol. May 28, 2016; 22(20): 4812-4823
Published online May 28, 2016. doi: 10.3748/wjg.v22.i20.4812
Published online May 28, 2016. doi: 10.3748/wjg.v22.i20.4812
Name | Indication | Line | Agent | ClinicalTrials.gov Identifier |
Phase | ||||
HER2 | ||||
HELOISE | HER2(+) Met GC and GEJ | 1st | Trastuzumab | NCT01450696 |
Phase III | ||||
JACOB | HER2(+) Met GC and GEJ | 1st | Pertuzumab | NCT01774786 |
Phase III | ||||
VEGFR | ||||
RAINFALL | HER2(-) Met GC and GEJ | 1st | Ramucirumab | NCT02314117 |
Phase III | ||||
PARP | ||||
Olaparib | Adv GC and GEJ | 2nd | Olaparib | NCT01924533 |
Phase III | ||||
Immune checkpoints | ||||
KEYNOTE-059 | Adv GC and GEJ | Pembrolizumab | NCT02335411 | |
Phase II | ||||
KEYNOTE-061 | Adv GC and GEJ | 2nd | Pembrolizumab | NCT02370498 |
Phase III | ||||
KEYNOTE-062 | Adv GC and GEJ | 1st | Pembrolizumab | NCT02494583 |
Phase III | ||||
MEDI4736 | Advanced solid tumors | MEDI4736 | NCT01693562 | |
Phase I/II | ||||
JAVELIN Gastric 100 | Adv/Met GC and GEJ | 1st | Avelumab | NCT02625610 |
Phase III | ||||
JAVELIN Gastric 300 | Met/recurrent GC and GEJ | 3rd | Avelumab | NCT02625623 |
Phase III | ||||
Phase I/II | Met/recurrent GC and GEJ | MEDI4736 + Tremelimumab vs MEDI4736 vs Tremelimumab | NCT02340975 | |
Phase I/II | Advanced solid tumors | Nivolumab +/- Ipilimumab | NCT01928394 |
- Citation: Jou E, Rajdev L. Current and emerging therapies in unresectable and recurrent gastric cancer. World J Gastroenterol 2016; 22(20): 4812-4823
- URL: https://www.wjgnet.com/1007-9327/full/v22/i20/4812.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i20.4812